Company profile
BioAdaptives Inc.
OTC: BDPT · Healthcare · Medical - Pharmaceuticals
#1116 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
29DFH 16DQ 35GM 59SS 21
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), growth stability · ↓ workforce scale, return on assets
Methodology →Revenue TTM
$25.6k
Rev growth YoY (TTM)
-169.7%
Net income (FY)
-$1.6M
Employees
1
as of 2026-08-29
Market cap
$16.8k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$18.3k$18.3k2025
Net income-$1.6M-$1.6M2025
Operating income-$1.0M-$1.0M2025
Total assets$225.9k$225.9k2025
Liabilities$2.4M$2.4M2025
Equity-$2.1M-$2.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioAdaptives Inc.’s revenue?
BioAdaptives Inc. booked $18.3k in FY2025 revenue, growing 44% year over year — faster than most Healthcare companies we track, at a -8523.4% net margin.
Neighbors
Clark →Key facts
CEOJames Keener
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersLas Vegas, NV
ExchangeOTC: BDPT
Employees1
IPO date2016-06-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.